Dicerna Pharmaceuticals Inc
F:DPL
| US |
|
Johnson & Johnson
NYSE:JNJ
|
Pharmaceuticals
|
| US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
Financial Services
|
| US |
|
Bank of America Corp
NYSE:BAC
|
Banking
|
| US |
|
Mastercard Inc
NYSE:MA
|
Technology
|
| US |
|
UnitedHealth Group Inc
NYSE:UNH
|
Health Care
|
| US |
|
Exxon Mobil Corp
NYSE:XOM
|
Energy
|
| US |
|
Pfizer Inc
NYSE:PFE
|
Pharmaceuticals
|
| US |
|
Palantir Technologies Inc
NYSE:PLTR
|
Technology
|
| US |
|
Nike Inc
NYSE:NKE
|
Textiles, Apparel & Luxury Goods
|
| US |
|
Visa Inc
NYSE:V
|
Technology
|
| CN |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
Retail
|
| US |
|
JPMorgan Chase & Co
NYSE:JPM
|
Banking
|
| US |
|
Coca-Cola Co
NYSE:KO
|
Beverages
|
| US |
|
Walmart Inc
NYSE:WMT
|
Retail
|
| US |
|
Verizon Communications Inc
NYSE:VZ
|
Telecommunication
|
| US |
|
Chevron Corp
NYSE:CVX
|
Energy
|
Utilize notes to systematically review your investment decisions. By reflecting on past outcomes, you can discern effective strategies and identify those that underperformed. This continuous feedback loop enables you to adapt and refine your approach, optimizing for future success.
Each note serves as a learning point, offering insights into your decision-making processes. Over time, you'll accumulate a personalized database of knowledge, enhancing your ability to make informed decisions quickly and effectively.
With a comprehensive record of your investment history at your fingertips, you can compare current opportunities against past experiences. This not only bolsters your confidence but also ensures that each decision is grounded in a well-documented rationale.
Do you really want to delete this note?
This action cannot be undone.
| 52 Week Range |
N/A
N/A
|
| Price Target |
|
We'll email you a reminder when the closing price reaches EUR.
Choose the stock you wish to monitor with a price alert.
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
Bank of America Corp
NYSE:BAC
|
US |
|
Mastercard Inc
NYSE:MA
|
US |
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
Pfizer Inc
NYSE:PFE
|
US |
|
Palantir Technologies Inc
NYSE:PLTR
|
US |
|
Nike Inc
NYSE:NKE
|
US |
|
Visa Inc
NYSE:V
|
US |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
Coca-Cola Co
NYSE:KO
|
US |
|
Walmart Inc
NYSE:WMT
|
US |
|
Verizon Communications Inc
NYSE:VZ
|
US |
|
Chevron Corp
NYSE:CVX
|
US |
This alert will be permanently deleted.
Net Margin
Dicerna Pharmaceuticals Inc
Net Margin measures how much net income is generated as a percentage of revenues received. It helps investors assess if a company's management is generating enough profit from its sales and whether operating costs and overhead costs are being contained.
Net Margin Across Competitors
| Country | Company | Market Cap |
Net Margin |
||
|---|---|---|---|---|---|
| US |
D
|
Dicerna Pharmaceuticals Inc
F:DPL
|
2.6B EUR |
-65%
|
|
| FR |
|
Pharnext SCA
OTC:PNEXF
|
6T USD |
-21 040%
|
|
| US |
|
Abbvie Inc
NYSE:ABBV
|
406B USD |
4%
|
|
| US |
|
Amgen Inc
NASDAQ:AMGN
|
176.8B USD |
19%
|
|
| US |
|
Gilead Sciences Inc
NASDAQ:GILD
|
153B USD |
28%
|
|
| US |
|
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
|
115.2B USD |
31%
|
|
| US |
E
|
Epizyme Inc
F:EPE
|
94.1B EUR |
-392%
|
|
| US |
|
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
|
81.5B USD |
32%
|
|
| AU |
|
CSL Ltd
ASX:CSL
|
83.3B AUD |
19%
|
|
| US |
|
Alnylam Pharmaceuticals Inc
NASDAQ:ALNY
|
52.4B USD |
1%
|
|
| NL |
|
argenx SE
XBRU:ARGX
|
43.6B EUR |
43%
|
Dicerna Pharmaceuticals Inc
Glance View
In the unassuming landscape of biotechnology, Dicerna Pharmaceuticals Inc. carved its niche with the finesse of a sculptor hewing masterpieces from marble. Founded in 2007, this Lexington-based company embarked on its journey into the realm of RNA interference (RNAi) therapies, a revolutionary approach that tackles diseases by silencing specific genes. RNAi is akin to flipping a switch within our genetic blueprint, modulating the expression of proteins that could potentially cause disorders. Dicerna's proprietary GalXC™ technology emerged as the linchpin of its innovation, allowing the company to create targeted therapies that had the potential to address a diverse array of rare and chronic diseases such as primary hyperoxaluria, chronic liver diseases, and viral infections. Dicerna's business model weaved together research prowess and strategic alliances, capitalizing on partnerships with big pharmaceutical titans like Novo Nordisk, Roche, Boehringer Ingelheim, and Eli Lilly to propel its research pipeline. These collaborations not only provided the necessary capital but also amplified its scientific discoveries to reach broader horizons. Licensing agreements allowed Dicerna to earn milestone payments along with royalties on eventual sales, enabling it to reinvest in groundbreaking research and development. While playing the long game in the volatile waters of biotechnology, Dicerna's revenue strategy relied heavily on these partnerships, as well as on advancing its in-house programs to bring its therapies closer to market, painting a picture of a company poised at the confluence of scientific promise and commercial potential.
See Also
Net Margin measures how much net income is generated as a percentage of revenues received. It helps investors assess if a company's management is generating enough profit from its sales and whether operating costs and overhead costs are being contained.
Based on Dicerna Pharmaceuticals Inc's most recent financial statements, the company has Net Margin of -64.5%.